Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Multiple Sclerosis l: Introduction01:19

Multiple Sclerosis l: Introduction

Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
Rheumatic Heart Disease I: Introduction01:23

Rheumatic Heart Disease I: Introduction

Rheumatic heart disease or RHD is a chronic condition that results from rheumatic fever, causing permanent damage to the heart valves.Etiology and Risk FactorsIt primarily arises from rheumatic fever, an inflammatory disease that can develop after untreated or inadequately treated group A streptococcal (GAS) pharyngitis. Streptococcus spreads through direct contact with oral or respiratory secretions. While the bacteria are the causative agents, factors like malnutrition, overcrowding, poor...
Cirrhosis II: Pathophysiology01:24

Cirrhosis II: Pathophysiology

Cirrhosis is a progressive chronic liver injury caused by prolonged inflammation, excessive fibrotic remodeling, and impaired regeneration. Over time, repeated hepatic insults disrupt the liver’s architecture and function, leading to reduced blood flow, impaired bile drainage, and diminished metabolic capacity.Pathophysiology of cirrhosisCirrhosis arises from three main responses to chronic liver damage: inflammation, immune activation, and hepatocyte death. These processes lead to structural...
Chronic Kidney Disease II: Clinical Manifestations01:24

Chronic Kidney Disease II: Clinical Manifestations

Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Non-genetic risk indicators for preterm birth: An umbrella review of systematic reviews and meta-analyses.

European journal of obstetrics, gynecology, and reproductive biology·2026
Same author

Requesting conflicts of interest declarations from the European Medicines Agency: 3-year follow-up status.

Epidemiology and psychiatric sciences·2024
Same author

Hundreds of thousands of zombie randomised trials circulate among us.

Anaesthesia·2020
Same author

Dental Research Waste in Design, Analysis, and Reporting: A Scoping Review.

Journal of dental research·2020
Same author

The role of meta-analyses and umbrella reviews in assessing the harms of psychotropic medications: beyond qualitative synthesis.

Epidemiology and psychiatric sciences·2018
Same author

Overlapping network meta-analyses on the same topic: survey of published studies.

International journal of epidemiology·2017

Related Experiment Video

Updated: Jun 27, 2026

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
04:44

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Published on: June 16, 2020

Mortality in systemic sclerosis.

F B Karassa1, J P A Ioannidis

  • 1Clinical and Molecular Epidemiology Unit and Clinical Trials and Evidence-based Medicine Unit, Department of Hygiene and Epidemiology, University of Ioannina School of Medicine, Ioannina, Greece.

Clinical and Experimental Rheumatology
|December 17, 2008
PubMed
Summary

Systemic sclerosis, a rare connective tissue disease, still causes significant excess mortality despite recent outcome improvements. This review examines mortality burden and predictors in scleroderma patients compared to the general population.

Related Experiment Videos

Last Updated: Jun 27, 2026

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
04:44

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Published on: June 16, 2020

Area of Science:

  • Rheumatology
  • Immunology
  • Epidemiology

Background:

  • Systemic sclerosis (SSc) is a rare, heterogeneous autoimmune connective tissue disease.
  • SSc presents diverse clinical manifestations, organ involvement, and variable disease courses.
  • Despite advances, SSc remains associated with substantial excess mortality.

Purpose of the Study:

  • To systematically review and synthesize published studies on mortality in SSc patients.
  • To compare SSc patient mortality with the general population.
  • To identify key predictors of mortality in systemic sclerosis.

Main Methods:

  • Systematic literature search for studies on SSc mortality and its predictors.
  • Analysis of published data comparing SSc mortality to general population rates.
  • Evaluation of studies investigating factors influencing SSc patient survival.

Main Results:

  • SSc patients experience significant excess mortality compared to the general population.
  • Certain clinical, immunological, and organ-specific factors are associated with increased mortality risk.
  • Methodological limitations in existing studies impact definitive conclusions.

Conclusions:

  • Systemic sclerosis continues to pose a significant mortality burden.
  • Further high-quality research is needed to refine understanding of SSc mortality predictors.
  • Improved study design and reporting are crucial for advancing SSc patient care and outcomes.